Clinical Trials
5 trialsNCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT03298984 2023-11-15
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT03563560 2022-04-12
AML
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT03441555 2022-02-01
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Completed